RU2009127351A - COMBINATIONS OF ANTIFOLATE AGENT IN TREATMENT OF CANCER - Google Patents
COMBINATIONS OF ANTIFOLATE AGENT IN TREATMENT OF CANCER Download PDFInfo
- Publication number
- RU2009127351A RU2009127351A RU2009127351/15A RU2009127351A RU2009127351A RU 2009127351 A RU2009127351 A RU 2009127351A RU 2009127351/15 A RU2009127351/15 A RU 2009127351/15A RU 2009127351 A RU2009127351 A RU 2009127351A RU 2009127351 A RU2009127351 A RU 2009127351A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- pemetrexed
- use according
- methoxyamine
- specified
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 8
- 201000011510 cancer Diseases 0.000 title claims abstract 8
- 239000004052 folic acid antagonist Substances 0.000 title 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims abstract 23
- 229960005079 pemetrexed Drugs 0.000 claims abstract 23
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims abstract 20
- 239000003814 drug Substances 0.000 claims abstract 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract 4
- 238000001990 intravenous administration Methods 0.000 claims abstract 4
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 2
- YLUGBQJQQLZZNL-UHFFFAOYSA-N O.O.O.O.O.O.O.[Na].[Na] Chemical compound O.O.O.O.O.O.O.[Na].[Na] YLUGBQJQQLZZNL-UHFFFAOYSA-N 0.000 claims abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 2
- 206010038389 Renal cancer Diseases 0.000 claims abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract 2
- 206010017758 gastric cancer Diseases 0.000 claims abstract 2
- 201000010982 kidney cancer Diseases 0.000 claims abstract 2
- 201000007270 liver cancer Diseases 0.000 claims abstract 2
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 2
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 2
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 2
- 201000011549 stomach cancer Diseases 0.000 claims abstract 2
- 230000002195 synergetic effect Effects 0.000 claims abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Применение 1) первой композиции, содержащей пеметрексед, и 2) второй композиции, содержащей метоксиамин, в изготовлении лекарственного средства, содержащего первую композицию, и лекарственного средства, содержащего вторую композицию, для лечения пациента, у которого диагностирован рак, выбранный из рака легкого, колоректального рака, рака яичника, рака поджелудочной железы, рака почки, рака эндометрия, рака желудка, рака печени и рака молочной железы. ! 2. Применение по п.1, где указанный рак представляет собой немелкоклеточный рак легких, колоректальный рак или рак молочной железы. ! 3. Применение по п.1, где указанный пеметрексед готовят в виде препарата для внутривенного или перорального введения. ! 4. Применение по п.1, где указанный метоксиамин готовят в виде препарата для внутривенного или перорального введения. ! 5. Применение по п.1, где указанный метоксиамин готовят в виде препарата для перорального введения. ! 6. Применение по п.1, где указанный метоксиамин и указанный пеметрексед вводят последовательно. ! 7. Применение по п.1 где указанный метоксиамин вводят перед пеметрекседом. ! 8. Применение по п.1, где указанный пеметрексед вводят перед метоксиамином. ! 9. Применение по п.1, где указанный пеметрексед в указанной первой композиции представляет собой гептагидратдинатриевой соли пеметрекседа. ! 10. Применение по п.1, где указанный метоксиамин готовят в виде препарата в количестве, достаточном для сенсибилизации указанного рака к указанному пеметрекседу. ! 11. Применение по п.1, где указанный метоксиамин и указанный пеметрексед достигают синергического эффекта при введении пациенту. !12. Применение по п.1, где указ� 1. The use of 1) a first composition containing pemetrexed, and 2) a second composition containing methoxyamine in the manufacture of a medicament containing the first composition and a medicament containing the second composition for treating a patient diagnosed with a cancer selected from lung cancer colorectal cancer, ovarian cancer, pancreatic cancer, kidney cancer, endometrial cancer, stomach cancer, liver cancer and breast cancer. ! 2. The use of claim 1, wherein said cancer is non-small cell lung cancer, colorectal cancer, or breast cancer. ! 3. The use according to claim 1, where the specified pemetrexed is prepared in the form of a preparation for intravenous or oral administration. ! 4. The use according to claim 1, where the specified methoxyamine is prepared in the form of a preparation for intravenous or oral administration. ! 5. The use according to claim 1, where the specified methoxyamine is prepared in the form of a preparation for oral administration. ! 6. The use according to claim 1, wherein said methoxyamine and said pemetrexed are administered sequentially. ! 7. The use according to claim 1, wherein said methoxyamine is administered before pemetrexed. ! 8. The use according to claim 1, where the specified pemetrexed is administered before methoxyamine. ! 9. The use according to claim 1, wherein said pemetrexed in said first composition is pemetrexed heptahydrate disodium. ! 10. The use according to claim 1, wherein said methoxyamine is prepared in the form of a preparation in an amount sufficient to sensitize said cancer to said pemetrexed. ! 11. The use according to claim 1, wherein said methoxyamine and said pemetrexed achieve a synergistic effect when administered to a patient. !12. The use according to claim 1, where
Claims (16)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87783606P | 2006-12-29 | 2006-12-29 | |
| US60/877,836 | 2006-12-29 | ||
| US88326607P | 2007-01-03 | 2007-01-03 | |
| US60/883,266 | 2007-01-03 | ||
| US60/883,959 | 2007-01-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009127351A true RU2009127351A (en) | 2011-02-10 |
| RU2423114C2 RU2423114C2 (en) | 2011-07-10 |
Family
ID=44740479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009127351/15A RU2423114C2 (en) | 2006-12-29 | 2007-12-21 | Combinations of antifolate agent in cancer treatment |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2423114C2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| AU2017308159B2 (en) * | 2016-08-12 | 2023-08-10 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| JP7514533B2 (en) | 2018-02-07 | 2024-07-11 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | Alpha polyglutamylated tetrahydrofolate and uses thereof |
| EP3749312A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | LOMETREXOL ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| CA3090483A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| JP7491572B2 (en) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | Alpha polyglutamated pemetrexed and uses thereof |
| WO2019157146A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| EP3749314A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | METHOTREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| CA3090387A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | PRALATREXATE GAMMA-POLYGLUTAMATE AND ASSOCIATED USES |
| US12290518B2 (en) | 2018-02-14 | 2025-05-06 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| CN100500215C (en) * | 2006-01-23 | 2009-06-17 | 济南帅华医药科技有限公司 | Sustained-release injection containing methotrexate and synergist thereof |
-
2007
- 2007-12-21 RU RU2009127351/15A patent/RU2423114C2/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2423114C2 (en) | 2011-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009127351A (en) | COMBINATIONS OF ANTIFOLATE AGENT IN TREATMENT OF CANCER | |
| ES2622559T3 (en) | Therapeutic combination comprising a cdk inhibitor and an antineoplastic agent | |
| CN101001623B (en) | Anticancer effect enhancer | |
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
| PT2127652E (en) | Method for treating cancer using anticancer agent in combination | |
| MXPA05003595A (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability. | |
| ES2605586T3 (en) | Etoposide analogues for the treatment of metastatic tumors | |
| CN103282037A (en) | Combination therapy of anti-tumor alkaloids | |
| RU2017134443A (en) | METHOD OF TREATMENT WITH USE OF TRADIPTANT | |
| JP2009539769A5 (en) | ||
| ES2889573T3 (en) | Multiple bolus administration of [6R]-MTHF in 5-fluorouracil-based chemotherapy | |
| NZ534914A (en) | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent in the treatment of cancer | |
| RU2010140890A (en) | IMPROVED METHODS OF ANTITUMOR TREATMENT | |
| JP2009515901A5 (en) | ||
| JP2009506054A5 (en) | ||
| JP2009536956A5 (en) | ||
| HRP20110250T1 (en) | OPTIMALIZATION OF PHILADELPHIA-POSITIVE LEUKEMIA TREATMENT WITH IMATINIB ABL-TYROSINE KINASE INHIBITOR | |
| RU2008138534A (en) | PHARMACEUTICAL COMBINATION FOR TREATMENT AND / OR CHEMOSENSIBILIZATION OF TUMORS RESISTANT TO ANTICANCERS | |
| CN109864991B (en) | Application of Cryptotanshinone in the Preparation of Ph+ Acute Lymphoblastic Leukemia Chemosensitizing Drugs | |
| RU2018131573A (en) | METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL FAILURE | |
| Kawahara et al. | Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas | |
| JP2011500650A5 (en) | ||
| Yamamoto et al. | Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study | |
| Chen et al. | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer |